Lutetium-177 DOTATATE

also known as: Lutathera, 177Lu-DOTATATE, Lutetium Lu 177 dotatate

A targeted radiotherapy peptide — a somatostatin analog armed with a radioactive warhead that delivers lethal radiation directly to neuroendocrine tumor cells expressing sst2 receptors.

An octreotide derivative (DOTA-Tyr3-octreotate) chelated with the beta-emitting radionuclide lutetium-177, providing peptide receptor radionuclide therapy (PRRT) by binding somatostatin receptor type 2 on neuroendocrine tumor cells and irradiating them from within.

Mechanism of action

The DOTATATE peptide binds sst2 with high affinity and is internalized via receptor-mediated endocytosis. Lutetium-177 emits beta particles (Emax 497 keV, range ~2 mm in tissue) that cause DNA double-strand breaks in the tumor cell and nearby cells (crossfire effect). The DOTA chelator stably binds ¹⁷⁷Lu, preventing systemic release. Kidneys and bone marrow are dose-limiting organs.

Primary uses

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Midgut carcinoid tumors
Pheochromocytoma/paraganglioma (investigational)
sst2-positive tumor research

Typical dosing

7.4 GBq (200 mCi) every 8 weeks × 4 doses (intravenous infusion)

4 doses total. Amino acid infusion (Lys/Arg) co-administered for renal protection. Prior sst2 positivity confirmed by ⁶⁸Ga-DOTATATE PET scan.

Regulatory status

FDA-approved in 2018 (Lutathera, Novartis/AAA) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Landmark NETTER-1 trial showed 79% reduction in risk of progression or death vs. octreotide LAR.

References

[clinical-trial] Strosberg J, et al. "Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1)." N Engl J Med, 2017;376:125-135.
[fda-pi] Lutathera (lutetium Lu 177 dotatate) Prescribing Information. Novartis.

Related peptides

Octreotide

The first-generation somatostatin analog (FDA-approved as Sandostatin, 1988) — the pharmacological counterweight to growth-hormone excess. Used for acromegaly, carcinoid syndrome, and VIPoma; now available in injectable, LAR-depot, and oral (Mycapssa, 2020) formulations.

Lanreotide

The second-generation somatostatin analog (FDA-approved as Somatuline Depot, 2007 for acromegaly; 2014 for GEP-NETs; 2017 for carcinoid) — monthly deep-SC prefilled syringe. Functionally equivalent to octreotide LAR for most indications.

Pasireotide

The somatostatin analog for Cushing's disease — the only FDA-approved medical therapy targeting pituitary ACTH secretion, with uniquely broad somatostatin receptor affinity.

Guides & tools

Explore with tools

Vendor Checklist → Reconstitution Calculator → Glossary → Beginner's Guide → All Research peptides →

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.